List view / Grid view

Articles

Issue 3 2017

Subvisible particle identification in protein-based formulations by Raman spectroscopy

29 June 2017 | By Markus Lankers (Rap.ID), Olga Laskina (Rap.ID), Oliver Valet (Rap.ID)

Subvisible particles in protein-based formulations can have different origins. Particles can be extrinsic (unexpected foreign material), intrinsic (from the production environment or primary packaging), and inherent (from the formulation). It is important that inherent particles (protein agglomerates) are distinguished from the other two types and that the extrinsic and intrinsic…

Issue 3 2017

Separation and purification applications for mutagenic impurities

29 June 2017 | By Dave Elder (JPAG Member and David P Elder Consultancy)

Classically, isolation of key intermediates and the resultant active pharmaceutical ingredient (API) has formed the basis of clean up and purification strategies within the pharmaceutical industry...

Personalised medicine, batch size of ONE, the new challenge to fill-finish?

29 June 2017 | By Wenzel Novak PhD | Market Development Director – Pharma | Optima Machinery Corporation

Wenzel Novak PhD gives some considerations on container, environment, process and automation for small batch sizes in the downstream process of fill-finish…

Issue 3 2017

Formulation Development & Delivery In-Depth Focus

29 June 2017 | By European Pharmaceutical Review

In this Formulation Development & Delivery In-Depth Focus: A report on the use of freeze-drying to develop orally disintegrating tablets; a review of mucosal drug delivery; an interview on drug delivery through the skin; and a profile of three analytical technologies used to develop drug delivery systems...

Issue 3 2017

Scientific Poster Gallery 2017

29 June 2017 | By European Pharmaceutical Review

In this supplement, we've brought together a collection of interesting posters from leading companies in order to celebrate cutting-edge research in the pharmaceutical industry and to share with our readers some of the varied work being carried out by their colleagues...

Issue 3 2017

Issue #3 2017 – Digital version

28 June 2017 | By European Pharmaceutical Review

In Issue #3 2017: In-Depth Focuses covering Raman Spectroscopy, Separations & Purifications, Formulation Development & Delivery; Guide To Testing Services; GMP and mutual recognition; Regulatory Insight; RMMs; Microbiology Series; and much more...

83% of life science leaders believe blockchain will be adopted within 5 years

27 June 2017 | By The Pistoia Alliance

Just under a quarter (22%) of life science companies already using or experimenting with blockchain, but industry collaboration over security and storage standards is needed…

Shire on Haemophilia: How to treat a bleeding disorder

26 June 2017 | By Naghmana Bajwa MD | Global Medical Affairs Haematology Lead | Shire

We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...

Risk, benefit or cost: What stops patients from receiving a diagnostic test?

12 June 2017 | By William Meurer (Michigan Medicine)

Diagnostic tests can help identify disease and disease probability in patients, leading to earlier treatment, but what’s the real cost?

Pharma Digitalisation: Challenges and opportunities in transforming the pharma industry

30 May 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Digitalisation and Sammeli Liikkanen, Chief Digital Officer, Orion Pharma

Pharma Digitalisation Executive Consultant, Pasi Kemppainen, and Orion’s CDO Sammeli Liikkanen talk technologies, challenges and opportunities with the digitalisation of pharma…

Why biosimilars are changing the pharmaceutical industry

26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare

We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…

Treating multiple myeloma: An interview with Janssen

17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA

We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...

Behind the numbers: The pharmaceutical industry and global health

10 May 2017 | By Cristina Arnés, IFPMA Policy Analyst, Regulatory Policy and Economic Affairs

IFPMA's top analyst examines future trends, biotherapeutics and personalised medicine, and explains why the industry needs to examine its economic footprint...

Biosimilars: the future of Pharma? An interview with Boehringer Ingelheim

3 May 2017 | By Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim

With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…

Issue 2 2017

Does the Falsified Medicines Directive lead to a European pack coding guideline?

22 April 2017 | By Johan Verhaeghe (Medicines for Europe)

The Directive on Falsified Medicines (FMD, or Directive 2011/62/EU amending Directive 2001/83/EC) and its supplementing Delegated Regulation (DR 2016/161) aim to improve patient safety by preventing falsified medicines from entering the legal supply chain...